Do analysts recommend MYNZ or ATYR?

aTyr Pharma has a consensus price target of $17.00, indicating a potential upside of 2,769.20%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Which has preferable valuation & earnings, MYNZ or ATYR?

Mainz Biomed has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 19.91 -$21.65M -$65.60 N/A aTyr Pharma $190K 305.76 -$74.12M -$0.73 N/A

Is MYNZ or ATYR more profitable?

Mainz Biomed's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A aTyr Pharma N/A -100.14% -73.55%

Do analysts rate FLNA or MYNZ?

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 306.50%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is FLNA or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Mainz Biomed N/A N/A N/A

Do analysts rate MYNZ or BHST?

BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 248.43%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate MYNZ or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MYNZ or TCRT more profitable?

Mainz Biomed's return on equity of 0.00% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Alaunos Therapeutics N/A -165.94% -123.50%

Do analysts prefer MYNZ or UPXI?

Upexi has a consensus price target of $8.10, indicating a potential upside of 820.45%. Given Upexi's stronger consensus rating and higher possible upside, analysts clearly believe Upexi is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Upexi 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation and earnings, MYNZ or UPXI?

Upexi has higher revenue and earnings than Mainz Biomed. Upexi is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 19.91 -$21.65M -$65.60 N/A Upexi $15.81M 3.91 -$13.68M -$0.62 N/A

Is MYNZ or UPXI more profitable?

Mainz Biomed has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Mainz Biomed's return on equity of 0.00% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Upexi -874.00% -66.70% -19.56%

Mainz Biomed (MYNZ) Competitors

$1.45 -0.09 (-5.84%)

As of 07/2/2026

Compare

MYNZ vs. ATYR, FLNA, BHST, TCRT, and UPXI

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include aTyr Pharma (ATYR), Cassava Sciences (FLNA), BioHarvest Sciences (BHST), Alaunos Therapeutics (TCRT), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to aTyr Pharma?

Mainz Biomed (NASDAQ:MYNZ) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

In the previous week, aTyr Pharma had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for aTyr Pharma and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
Mainz Biomed	Neutral
aTyr Pharma	Neutral

61.7% of aTyr Pharma shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

aTyr Pharma has a consensus price target of $17.00, indicating a potential upside of 2,769.20%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Mainz Biomed has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	19.91	-$21.65M	-$65.60	N/A
aTyr Pharma	$190K	305.76	-$74.12M	-$0.73	N/A

Mainz Biomed's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
aTyr Pharma	N/A	-100.14%	-73.55%

Summary

aTyr Pharma beats Mainz Biomed on 9 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Mainz Biomed	N/A	N/A	N/A

38.1% of Cassava Sciences shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 306.50%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Mainz Biomed	$659.94K	19.91	-$21.65M	-$65.60	N/A

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Mainz Biomed	Neutral

Summary

Mainz Biomed beats Cassava Sciences on 7 of the 12 factors compared between the two stocks.

How does Mainz Biomed compare to BioHarvest Sciences?

Mainz Biomed (NASDAQ:MYNZ) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Mainz Biomed has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Mainz Biomed's return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

BioHarvest Sciences has higher revenue and earnings than Mainz Biomed. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	19.91	-$21.65M	-$65.60	N/A
BioHarvest Sciences	$34.51M	1.63	-$11.14M	-$0.59	N/A

In the previous week, Mainz Biomed's average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score.

Company	Overall Sentiment
Mainz Biomed	Neutral
BioHarvest Sciences	Neutral

BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 248.43%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioHarvest Sciences beats Mainz Biomed on 7 of the 12 factors compared between the two stocks.

How does Mainz Biomed compare to Alaunos Therapeutics?

Mainz Biomed (NASDAQ:MYNZ) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Mainz Biomed's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Alaunos Therapeutics has lower revenue, but higher earnings than Mainz Biomed. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	19.91	-$21.65M	-$65.60	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

In the previous week, Alaunos Therapeutics had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Alaunos Therapeutics and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 beat Alaunos Therapeutics' score of -0.30 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Alaunos Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.7% of Alaunos Therapeutics shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, suggesting that its share price is 202% less volatile than the broader market.

Summary

Mainz Biomed beats Alaunos Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Mainz Biomed compare to Upexi?

Mainz Biomed (NASDAQ:MYNZ) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Upexi has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market.

In the previous week, Upexi had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Upexi and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 beat Upexi's score of -0.20 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Upexi	Neutral

Upexi has higher revenue and earnings than Mainz Biomed. Upexi is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	19.91	-$21.65M	-$65.60	N/A
Upexi	$15.81M	3.91	-$13.68M	-$0.62	N/A

Upexi has a consensus price target of $8.10, indicating a potential upside of 820.45%. Given Upexi's stronger consensus rating and higher possible upside, analysts clearly believe Upexi is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Upexi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Mainz Biomed has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Mainz Biomed's return on equity of 0.00% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Upexi	-874.00%	-66.70%	-19.56%

5.7% of Upexi shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 9.0% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Mainz Biomed and Upexi tied by winning 8 of the 16 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.14M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.02	21.61	28.02	24.70
Price / Sales	19.91	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.56	8.66	10.96	6.46
Net Income	-$21.65M	$23.81M	$3.57B	$337.01M
7 Day Performance	-11.04%	3.39%	2.12%	1.69%
1 Month Performance	-37.77%	10.81%	5.25%	3.81%
1 Year Performance	0.69%	62.61%	33.29%	23.90%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	0.2583 of 5 stars	$1.45 -5.8%	N/A	+0.7%	$13.14M	$659.94K	N/A	30	High Trading Volume
ATYR aTyr Pharma	3.0201 of 5 stars	$0.59 +3.6%	$17.00 +2,796.1%	-88.7%	$57.56M	$190K	N/A	53	News Coverage
FLNA Cassava Sciences	1.5764 of 5 stars	$1.19 -2.5%	$5.00 +320.2%	-38.8%	$57.49M	N/A	N/A	20	Positive News
BHST BioHarvest Sciences	3.1464 of 5 stars	$2.90 +3.8%	$10.00 +245.4%	-58.4%	$56.79M	$35.16M	N/A	N/A	Positive News Gap Up
TCRT Alaunos Therapeutics	0.7899 of 5 stars	$2.30 -3.0%	N/A	-58.5%	$56.15M	$3K	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. ATYR, FLNA, BHST, TCRT, and UPXI

How does Mainz Biomed compare to aTyr Pharma?

Summary

How does Mainz Biomed compare to Cassava Sciences?

Summary

How does Mainz Biomed compare to BioHarvest Sciences?

Summary

How does Mainz Biomed compare to Alaunos Therapeutics?

Summary

How does Mainz Biomed compare to Upexi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. ATYR, FLNA, BHST, TCRT, and UPXI

How does Mainz Biomed compare to aTyr Pharma?

Which has more volatility & risk, MYNZ or ATYR?

Does the media refer more to MYNZ or ATYR?

Do institutionals & insiders believe in MYNZ or ATYR?

Do analysts recommend MYNZ or ATYR?

Which has preferable valuation & earnings, MYNZ or ATYR?

Is MYNZ or ATYR more profitable?

Summary

How does Mainz Biomed compare to Cassava Sciences?

Which has more risk & volatility, FLNA or MYNZ?

Is FLNA or MYNZ more profitable?

Do insiders & institutionals have more ownership in FLNA or MYNZ?

Do analysts rate FLNA or MYNZ?

Which has better valuation & earnings, FLNA or MYNZ?

Does the media prefer FLNA or MYNZ?

Summary

How does Mainz Biomed compare to BioHarvest Sciences?

Is MYNZ or BHST more profitable?

Which has more volatility and risk, MYNZ or BHST?

Which has stronger valuation and earnings, MYNZ or BHST?

Does the media prefer MYNZ or BHST?

Do analysts rate MYNZ or BHST?

Summary

How does Mainz Biomed compare to Alaunos Therapeutics?

Is MYNZ or TCRT more profitable?

Which has better earnings & valuation, MYNZ or TCRT?

Does the media refer more to MYNZ or TCRT?

Do analysts rate MYNZ or TCRT?

Do institutionals & insiders have more ownership in MYNZ or TCRT?

Which has more risk and volatility, MYNZ or TCRT?

Summary

How does Mainz Biomed compare to Upexi?

Which has more risk and volatility, MYNZ or UPXI?

Does the media favor MYNZ or UPXI?

Which has better valuation and earnings, MYNZ or UPXI?

Do analysts prefer MYNZ or UPXI?

Is MYNZ or UPXI more profitable?

Do insiders & institutionals have more ownership in MYNZ or UPXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools